NCT04508309View on ClinicalTrials.gov

Phase 3 Trial of a Bivalent Human Papilloma Virus (HPV) Vaccine (Cecolin®) in Young Girls

PHASE3CompletedINTERVENTIONAL
Enrollment

1,025

Participants

Timeline

Start Date

March 15, 2021

Primary Completion Date

December 14, 2023

Study Completion Date

December 14, 2023

Conditions
Cervical Cancer
Interventions
BIOLOGICAL

Cecolin®

Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine

BIOLOGICAL

Gardasil®

Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine

Trial Locations (2)

Unknown

International Centre for Diarrhoeal Disease Research, Dhaka

Malaria Research Centre, Agogo Presbyterian Hospital, Agogo

All Listed Sponsors
collaborator

International Centre for Diarrhoeal Disease Research, Bangladesh

OTHER

collaborator

Malaria Research Centre, Agogo Presbyterian Hospital, Ghana

UNKNOWN

collaborator

Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., USA

UNKNOWN

collaborator

The Emmes Company, LLC

INDUSTRY

collaborator

Xiamen Innovax Biotech Co., Ltd

INDUSTRY

lead

PATH

OTHER

NCT04508309 - Phase 3 Trial of a Bivalent Human Papilloma Virus (HPV) Vaccine (Cecolin®) in Young Girls | Biotech Hunter | Biotech Hunter